LEAP2

Across TCGA pan-cancer cohorts, LEAP2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LEAP2 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LEAP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LEAP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD and CCRCC are the cancer types where LEAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.703	0.389	.031	4	view →
CCRCC	DFS	Quartile	All	0.642	0.858	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

LEAP2–LUAD (DFS)

Open the LUAD breakdown →